Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 1
2009 1
2011 3
2012 1
2013 2
2014 1
2015 1
2016 4
2017 13
2018 10
2019 12
2020 21
2021 14
2022 8
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. Seymour L, et al. Among authors: caramella c. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28271869 Free PMC article. Review.
Tumour burden and efficacy of immune-checkpoint inhibitors.
Dall'Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, Besse B. Dall'Olio FG, et al. Among authors: caramella c. Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12. Nat Rev Clin Oncol. 2022. PMID: 34642484 Review.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. Among authors: caramella c. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, Sabari JK, Caramella C, Plodkowski AJ, Halpenny D, Chaft JE, Planchard D, Riely GJ, Besse B, Hellmann MD. Arbour KC, et al. Among authors: caramella c. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20. J Clin Oncol. 2018. PMID: 30125216 Free article.
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, Kunz W, Belkacemi Y, Bau MG, Caramella C, De Geus-Oei LF, De Caluwé A, Deroose C, Gheysens O, Herrmann K, Kindts I, Kontos M, Kümmel S, Linderholm B, Lopci E, Meattini I, Smeets A, Kaidar-Person O, Poortmans P, Tsoutsou P, Hajjaji N, Russell N, Senkus E, Talbot JN, Umutlu L, Vandecaveye V, Verhoeff JJC, van Oordt WMH, Zacho HD, Cardoso F, Fournier L, Van Duijnhoven F, Lecouvet FE. Pasquier D, et al. Among authors: caramella c. Lancet Oncol. 2023 Aug;24(8):e331-e343. doi: 10.1016/S1470-2045(23)00286-3. Lancet Oncol. 2023. PMID: 37541279 Review.
Impact of the COVID-19 crisis on imaging in oncological trials.
Deroose CM, Lecouvet FE, Collette L, Oprea-Lager DE, Kunz WG, Bidaut L, Verhoeff JJC, Caramella C, Lopci E, Tombal B, de Geus-Oei LF, Fournier L, Smits M, deSouza NM. Deroose CM, et al. Among authors: caramella c. Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2054-2058. doi: 10.1007/s00259-020-04910-y. Eur J Nucl Med Mol Imaging. 2020. PMID: 32533240 Free PMC article. No abstract available.
Lung cancer screening: French radiologists should prepare for it.
Lederlin M, de Margerie-Mellon C, Boussouar S, Bommart S, Caramella C. Lederlin M, et al. Among authors: caramella c. Diagn Interv Imaging. 2021 Apr;102(4):197-198. doi: 10.1016/j.diii.2021.02.004. Epub 2021 Feb 25. Diagn Interv Imaging. 2021. PMID: 33642220 Free article. No abstract available.
AZTEK: Adaptive zero TE k-space trajectories.
Boucneau T, Fernandez B, Besson FL, Menini A, Wiesinger F, Durand E, Caramella C, Darrasse L, Maître X. Boucneau T, et al. Among authors: caramella c. Magn Reson Med. 2021 Feb;85(2):926-935. doi: 10.1002/mrm.28483. Epub 2020 Sep 16. Magn Reson Med. 2021. PMID: 32936490 Free article.
Advances in oncological treatment: limitations of RECIST 1.1 criteria.
Grimaldi S, Terroir M, Caramella C. Grimaldi S, et al. Among authors: caramella c. Q J Nucl Med Mol Imaging. 2018 Jun;62(2):129-139. doi: 10.23736/S1824-4785.17.03038-2. Epub 2017 Nov 22. Q J Nucl Med Mol Imaging. 2018. PMID: 29166754 Free article. Review.
85 results